Cardiac resynchronization therapy
Ask the expert
The report presents a summary of reimbursement situation for cardiac resynchronization therapy.
Both Cardiac Resynchronization Therapy Pacemaker (CRT-P) and Cardiac Resynchronization Therapy Defibrillator (CRT-D) are considered.
Reimbursement analysis will cover the following procedures:
- Implantation of CRT system
- Replacement of CRT system
- Removal of CRT system
The following indications will be considered:
- Congestive heart failure
- Ventricular tachycardia
The only reimbursement within public / statutory health insurance systems is considered.
Report includes essential information about reimbursement and national funding, including:
- Brief overview of reimbursement system for medical devices
- Procedure coding for technology
- Diagnosis coding
- Payment mechanism for technology
- Reimbursement tariffs for technology
- Restrictions in indications or scenarios for use of technology
- Policy considerations by payers and policy-makers about technology
Reimbursement information is provided for the following geographies:
- England (UK)
It is also possible to add analysis in Czech Republic, Finland, Hungary, Romania, Russia and Turkey.
Manufacturers of devices for cardiac resynchronization system (CRT and CRT-D) include:
- Abbott Vascular (Quadra Allure, Quadra Assura)
- Biotronik (Inventra 7HF-T, Intica CRT-DX ProMRI, Ilvia -HF-T QP ProMRI, Etrinsa 8HF-T, Edora 8 HF-T QP)
- Boston Scientific (Dynagen X4, Inogen, Momentum, Resonate, Vigilant, Valitude X4, Intua, Invive)
- MicroPort (Reply, Platinium)
Table of content is not available at the moment. Report is still ongoing.
On December 17, 2021, NHS Digital released HRG4+ Consultation Grouper for 2022/23. This release is used to support the NHS England and Improvement consultation process for the 2022/23 National Tariff Payment System. In general, there are significant changes in base HRG design. A total of 120 new HRGs were created, multiple HRGs were removed, and the grouping logic was updated significantly. This Consultation Grouper will be superseded by the 2022/23 Local Payment Grouper in March 2022, for use from April 01, 2022.Read more
On November 9, 2021, the Belgian Health Care Knowledge Center (KCE) published the health technology assessment report "Remote monitoring of patients with cardiovascular implantable electronic devices (CIED)". Analysis of efficacy and safety of remote monitoring showed an advantage in various aspects. Cost-effectiveness analysis indicates that remote cardiac monitoring of ICDs and PMs is cost-effective compared to monitoring based on in-clinic visits.Read more
In late September 2021, the Austrian version of the DRG system (LKF) 2022 model with the relevant supplementary documents was published in Austria. The document "Changes and innovations in the 2022 LKF model" (Änderungen und Neuerungen in den LKF-Modellen 2022) summarizes the most significant changes and innovations in the LKF model for inpatient and outpatient care. The newly added procedure codes concern mainly the cardiovascular, E-Health, and gastrointestinal area.Read more
In mid-June 2021, the document "Changes and innovations in the 2022 LKF model" (Änderungen und Neuerungen in den LKF-Modellen 2022) was published. The document summarizes the most significant changes and innovations in the LKF model for inpatient and outpatient care. The newly added procedure codes concern mainly the cardiovascular, e-Health, and gastrointestinal area.Read more
On January 29, 2021, the Institute for the Hospital Remuneration System (InEK) has published the List of the requests for innovation funding (NUB) that were submitted by the hospitals in 2020. The medical technologies belonging to the cardiovascular, ENT, eHealth, gastrointestinal, neuromodulation, neurovascular, orthopedic, and other technology groups obtained positive status 1.Read more